Table 1 Nodal pathologic complete response in triple-negative/HER2 positive breast cancers, and in hormone receptor-positive and HER2 negative breast cancers.
Study | No. of patients (stage) | HR positive/HER2 negative | TNBC | HER2 positive |
|---|---|---|---|---|
Boughey 2013 | 756 (pN+) | 21% | 49% | 65% |
Kim 2015 | 415 (pN+) | 29% | 54% | 49% |
Montagna 2020 | 573 (pN+) | 20% | 44% | 63.3% |
Simons 2019 | 139 (pN+) | 7.4% | 44% | 74% |
